MAPT and Alzheimer disease: However, most of these studies have been performed in animal models of AD.[223] Caffeine's capacity to inhibit nonselective adenosine receptors,[224] reduce Aβ and tau aggregates, and reduce cognitive impairments suggests this molecule is a promising candidate for treating AD,[223] even though it has not yet been established as a therapy.